In preclinical studies, combining the IRAK4 inhibitor AS2444697 or IL-1β-neutralizing antibodies with gemcitabine significantly suppressed tumor growth and reduced fibrosis, highlighting the therapeutic potential of disrupting this signaling loop (107). This evidence concerns the gene IRAK4 and neoplasm.